Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.60 |
| ▸ | AKT2 | P31751 | 1/20 | 0.56 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.56 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059867 | 0.86 | AKT1 (0.60) | AKT1AKT2AKT1S1AKT3DPP4 | |
| SCHEMBL7214004 | 0.85 | HSD17B10 (0.71) | AKT1AKT2AKT3DPP4 | |
| SCHEMBL11226904 | 0.85 | HSD17B10 (0.71) | AKT1AKT2AKT3DPP4 | |
| SCHEMBL27154397 | 0.85 | HSD17B10 (0.71) | AKT1AKT2AKT3DPP4 | |
| Hydrochloric Acid SCHEMBL6898277 | 0.84 | HDAC8 (0.69) | AKT1AKT2AKT3DPP4 | |
| Hydrochloric Acid SCHEMBL27547045 | 0.84 | HDAC8 (0.69) | AKT1AKT2AKT3DPP4 | |
| SCHEMBL14279733 | 0.82 | MC4R (0.55) | AKT1AKT2AKT1S1AKT3DPP7 | |
| Hydrochloric Acid SCHEMBL3791647 | 0.82 | UGCG (0.50) | AKT1DPP7 | |
| Hydrochloric Acid SCHEMBL3791640 | 0.82 | UGCG (0.50) | AKT1DPP7 | |
| SCHEMBL3424349 | 0.81 | OPRD1 (0.46) | AKT1DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | AKT1 3114/4885AKT2 2960/4885AKT1S1 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.